Supernus Reports Rapid Antidepressant Effects of SPN-820 in Phase 2 Trials

Supernus Pharmaceuticals, a biopharmaceutical company dedicated to central nervous system diseases, has been at the forefront of developing innovative treatments for conditions like major depressive disorder (MDD). The company recently reported promising results from its Phase 2a trial of SPN-820, an mTORC1 activator designed to rapidly reduce depressive symptoms. The trial demonstrated significant improvements, with rapid reduction in scores on both the Hamilton Depression Rating Scale and the Montgomery Åsberg Depression Rating Scale, signaling clinically meaningful changes in patients with MDD[1][2].